A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
A Multicohort, Open Label, Phase 2 Study of Botensilimab (AGEN1181) for Treatment of Advanced Melanoma Refractory to Prior Checkpoint Inhibitor Therapy
Sponsor: Agenus Inc.
A PHASE2 clinical study on Advanced Melanoma, this trial is ongoing. The trial is conducted by Agenus Inc. and has accumulated 14 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
-
Apr 2025 — Sep 2025 [monthly]
Active Not Recruiting PHASE2
-
Jan 2025 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
Status: Suspended → Active Not Recruiting
-
Sep 2024 — Jan 2025 [monthly]
Suspended PHASE2
▶ Show 9 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Suspended PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Oct 2023 — Feb 2024 [monthly]
Recruiting PHASE2
-
May 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — May 2023 [monthly]
Recruiting PHASE2
-
Jan 2023 — Apr 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Dec 2022 — Jan 2023 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Agenus Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Barcelona, Spain , Boston, United States , Donostia / San Sebastian, Spain , Essen, Germany , Fullerton, United States , Hackensack, United States , Hamburg, Germany , Heidelberg, Germany , Ijuí, Brazil and 33 more locations